Nina Peterson, CANS
Nina Peterson is a Certified Aesthetic Nurse Specialist (CANS) specializing in facial contouring and non-surgical mini facelifts with PDO threads. With over nine years of experience gained in dermatology and plastic surgery practices, Nina also works as a medical blogger and consultant for aesthetic practices and licensed individuals, bringing her background in plastic surgery and dermatology to provide valuable insights.
author’s articles

Forehead Filler: Breaking the Taboo
Forehead filler remains a debated topic due to the inherent risks associated with the region’s vascular anatomy. The FDA has...
Read More
Is Liporase FDA Approved?
FDA approval serves as a crucial safeguard in the medical field, ensuring that treatments meet rigorous standards for safety and...
Read More
How to Dilute Liporase – Step-by-Step Guidance
Recent advances in aesthetic medicine highlight the critical role of precise dilution when using hyaluronidase. A guidance document by King,...
Read More
How Long Does Entyvio Take to Work?
A recent study published in the Journal of Crohn’s and Colitis analyzed data from 13,222 patients with inflammatory bowel disease...
Read More
Entyvio Manufacturer – About Takeda Oncology
According to a recent study in BMC Public Health, approximately 405,000 new cases of inflammatory bowel disease (IBD) are diagnosed...
Read More
Entyvio and Pregnancy – Is It Safe?
A 2023 narrative review in Reproductive Medicine revealed that pregnant individuals with active inflammatory bowel disease (IBD) face significantly higher...
Read More
Entyvio Generic Name – About Vedolizumab
Recent systematic reviews indicate that vedolizumab, the generic name for Entyvio, significantly improves clinical outcomes in patients with inflammatory bowel...
Read More
Entyvio for Crohn’s Disease – Is It Effective?
Nearly 790,000 Americans are estimated to live with Crohn’s disease, underscoring the significant public health challenge posed by this chronic...
Read More
Entyvio Prescribing Information – Clinical Considerations for Physicians
A recent Phase 4 EARNEST study reported that vedolizumab induced clinical remission in 31% of patients by Week 14, compared...
Read More
Entyvio Pen vs Infusion – How Do They Differ?
Clinical trials have demonstrated that biologic therapies like Entyvio (vedolizumab) can achieve remission rates of up to 47% by week...
Read More